Trust Chem Co. Ltd. Overview
Trust Chem is China's largest exporter of organic pigments, ranked first in national organic-pigment exports every year from 2015 to 2025 by the Organic Pigment Committee of the China Dyestuff Industry Association. Historically an asset-light "colourant solutions" house, it combines application-driven product development, proprietary testing and quality control, upstream supply-chain integration and a global, localised sales and warehousing network across 70–80+ countries, selling more than 450 pigment specifications under its own brand to multinational ink, coating and plastics producers such as DIC, Flint Group, Siegwerk, Sherwin-Williams and Axalta. Roughly 80–88% of revenue is earned outside China. Since 2023 it has been moving upstream into owned manufacturing through two subsidiaries in Jinzhou, Liaoning, and its July 2026 convertible-bond plan (≤ CNY 450M) would fund high-performance post-treatment capacity. The investment case hinges on whether vertical integration can lift structurally thin (~15–18%) gross margins without eroding its trading-model agility.
Company's own description (2026 Interim Report, Section III)
The company states that it is principally engaged in the product development, production, sale and servicing of organic pigments and other colourants. Its core competitiveness is defined as product development, quality management, supply-chain integration and a global sales network. Main products are organic pigments (azo, heterocyclic, phthalocyanine and others) and acid dyes. Organic pigments are applied in inks, coatings, plastics and specialty applications; acid dyes are used for dyeing textile fibres (nylon, wool, silk and blends), inkjet inks and waterborne wood lacquers. The company emphasises that downstream application diversity, customer habits and regional differences create extensive demand for customised and personalised pigment products, and that large international customers impose stringent requirements on application development capability, quality, management systems, compliance, geographic coverage and responsiveness.
The stated operating model is a five-link chain: (1) obtain and analyse customer requirements; (2) develop products; (3) manage the supply chain; (4) test products and control quality; (5) sell under the company's own brand.
Operating sub-models
Procurement: Because no single pigment manufacturer can cover the breadth of downstream needs, Trust Chem integrates upstream suppliers who produce to its specifications, and maintains a "qualified supplier list" refreshed through periodic assessments. Per the IPO risk disclosure, purchased finished pigments accounted for 94.88% (FY2021), 93.05% (FY2022), 93.64% (FY2023) and 88.94% (1H2024) of main-business cost — demonstrating that the company has been overwhelmingly a branded integrator rather than a manufacturer.
Sales: Predominantly export-led, combining a Hangzhou headquarters sales team with localised overseas teams. Orders flow through an ERP system to procurement and technical service; product-development requests go to R&D. The company maintains overseas warehousing so it can serve safety-stock requirements and deliver quickly.
R&D: A synthesis laboratory (new pigment development) and application laboratories for coatings, plastics and inks that simulate customers' use conditions. New-product development follows a project-team model led by R&D with multi-department participation, staged from demand investigation through feasibility, design, sampling, testing, review and acceptance.
Own production: Described as a "supplement and improvement" to the supply chain — validating R&D projects at the company's own production bases before supply. The Jinzhou (Liaoning) bases are positioned in the CB filings as the group's "technology transformation base for high-quality, high-value-added, safer and more environmentally friendly products."
Revenue model and mix
| Dimension | Characterisation |
|---|---|
| Product vs. service | ~99% product sales (chemical industry); "other business" 0.96% of 1H2026 revenue |
| Subscription / licensing | None disclosed |
| Pricing basis | Transactional, quoted in USD/EUR for exports; forward FX quoting used to pass through currency risk |
| Revenue recognition | FOB/CIF/CFR on bill of lading; DDU/DAP/DDP on customer receipt; consignment on monthly reconciliation (2026 Interim Report, Note V.37) |
| Customer concentration | Top-5 receivables = 32.66% of receivables at 30 Jun 2026 (largest 12.47%) |
Value-chain position
Trust Chem sits between Chinese pigment producers (upstream: petrochemical and coal-chemical intermediates → pigment synthesis) and multinational formulators (downstream: printing inks, industrial and decorative coatings, plastics masterbatch). Its value-add is specification design, application testing, regulatory compliance (REACH, MSDS in ~30 languages), brand assurance and logistics. It is now adding a manufacturing layer (azo dyes/pigments and high-quality organic pigments in Jinzhou) and, if the CB is completed, a post-treatment ("high-performance-isation") layer that would upgrade both self-made and outsourced pigments.
Customer types and end-markets
| End-market | Application | Representative customers named in filings |
|---|---|---|
| Printing inks | Packaging, publication, specialty inks | DIC Corporation, Flint Group, Siegwerk |
| Coatings | Industrial, decorative, automotive refinish | Sherwin-Williams, Axalta |
| Plastics | Masterbatch, compounds | Not named |
| Textiles (acid dyes) | Nylon, wool, silk dyeing | Not named |
| Specialty | Inkjet inks, waterborne wood lacquers, stationery | Not named |
The CB feasibility report (Jul 2026) states core customer relationships exceed ten years and switching costs are high.
Independent characterisation
Trust Chem is best understood as a global specialty-chemicals distributor-integrator with brand and compliance moats, in transition toward partial vertical integration. Its gross margins (~14–18%) are closer to a sophisticated distributor than to a pigment manufacturer (domestic HPP producers such as Qicai Chemical report ~29% gross margin), but its returns on equity were historically high (derived ~17–22% in FY2022–FY2024) because the model was capital-light. The pivot to owned manufacturing in Liaoning has raised the asset base (total assets up from CNY 983M in FY2021 to CNY 2,026M at 1H2026) while the manufacturing subsidiaries have so far been loss-making (Liaoning Xinkai net loss CNY 24.97M in FY2024), compressing ROE (derived ~9.5% in FY2025). The core strategic question for investors is therefore one of capital allocation: whether manufacturing brings margin uplift and supply security commensurate with the capital and execution risk.
Strategy
Stated strategy themes (2026 Interim Report; CB filings)
The company frames its strategy around four pillars, paraphrased from filings:
-
High-end manufacturing upgrade — moving from supply-chain integration to selective owned production and post-treatment to raise value added and margins ("提升高端化生产制造能力").
-
Globalised marketing and service network — deepening localised sales teams, warehousing and logistics to increase customer stickiness.
-
Digital and intelligent group platform — rebuilding a global ERP to integrate R&D, manufacturing, logistics and finance across 15 entities, and preparing for AI tooling.
-
Green and compliant growth — leveraging REACH registrations and EHS systems as market-access barriers, and building owned environmental infrastructure.
Press coverage of the 1H2025 results describes management's narrative as "globalisation and green transformation dual-wheel drive", pointing to stricter EU REACH restrictions and US supply-chain scrutiny as forces accelerating the shift toward high-end, green pigments.
Initiatives in the last 24 months
| Initiative | Date | Scope / target | Status |
|---|---|---|---|
| IPO and use of proceeds | Apr 2025 | CNY 243.85M net: R&D Centre & HQ (CNY 164.63M) and bank loan repayment (CNY 79.23M) | 73.3% of proceeds used at 30 Jun 2026; loan repayment complete; R&D centre 68% complete, delayed to Jun 2027 |
| 1,500 t high-quality organic pigment project | Ongoing | Budget CNY 229.99M; self-funded and bank loans | 92.31% complete (1H2026) |
| Liaoning Xinkai 10,000 t azo dye/pigment project | Commissioned ~2023 | Supported by CNY 28.16M subsidy | Ramping; subsidiary loss-making in FY2024 |
| Shanghai logistics centre lease | Jun 2025 | 5,500 m², three years | Operating |
| Convertible bond (≤ CNY 450M) | Announced 7 Jul 2026 | Five projects (see below) | Pending shareholder approval/exchange review/CSRC registration |
| FX hedging programme | Renewed Apr–May 2026 | Forward contracts matched to receipts | Ongoing; CNY 0.39M realised gain 1H2026 |
| CNY 1.2bn bank credit line | Approved Jun 2025 | Group-wide revolving facilities | Ongoing |
| Project | Total investment (CNY Mn) | Proceeds (CNY Mn) | Implementer | Notes |
|---|---|---|---|---|
| Dye/pigment high-performance post-treatment project | 230.0 | 230.0 | Liaoning Xinkai | Construction CNY 215M + working capital CNY 15M; Jinzhou; land secured; filing and EIA in progress |
| 1,500 t/day wastewater treatment project | 45.0 | 45.0 | Liaoning Ziyuan | Within existing site; no direct profit |
| Global marketing service network upgrade | 80.0 | 80.0 | Parent, Trust Chem Europe, Trust Chem USA | Warehouse leasing CNY 53M, personnel CNY 15M, equipment CNY 12M |
| Global digital/intelligent ERP system | 20.0 | 20.0 | Parent | Development CNY 10M, hardware CNY 5M, licences CNY 5M |
| Bank loan repayment | 75.0 | 75.0 | Parent | Against ~CNY 336M bank loans |
| Total | 450.0 | 450.0 | — | — |
Sustainability/ESG commitments
No quantified emissions targets or ESG commitments were found in the filings reviewed. The wastewater project and the "safer, more environmentally friendly products" positioning of the Liaoning base are the main environmental initiatives.
Medium-term financial targets / guidance
Management has not published revenue, margin or earnings guidance. The CB dilution announcement uses illustrative scenarios (flat, +10% and +20% annual growth in net profit from the FY2025 base of CNY 77.82M) explicitly stated not to constitute forecasts. The company has not adopted a market-value management system or a valuation enhancement plan, and has not published a "quality and returns dual improvement" action plan (2026 Interim Report).
Products & Services
Azo pigments (60.3% of 1H2026 revenue)
Description: Azo-based organic pigments, which include most "classic organic pigments" (CLP): lake pigments, naphthol (色酚) types, diarylide (benzidine) yellows, pyrazolones and monoazo yellows (company glossary).
Key properties: High tinting strength, bright shades, ease of grinding and dispersion; fastness (weather and light) inferior to high-performance pigments (HPP).
Target customers: Printing-ink manufacturers (packaging and publication), indoor coatings, plastics.
Capacity: Liaoning Xinkai's 10,000-tonne azo dye/pigment project (commissioning from ~Oct 2023; ramp ongoing).
Gross margin: 18.09% (1H2026); 15.14% (FY2025); 13.92% (FY2024).
Pricing model: Transactional, USD/EUR quotation; not disclosed.
Heterocyclic pigments (22.4% of 1H2026 revenue)
Description: Heterocyclic-structure pigments generally belonging to the high-performance class (company does not name sub-families in the documents reviewed; industry classification typically includes quinacridones, diketopyrrolopyrroles, dioxazines, isoindolines and similar).
Key properties (HPP glossary): Superior lightfastness, weatherfastness, heat resistance and solvent resistance; strong application performance (dispersion, rheology, storage stability); priced above CLP.
Target customers: Industrial and automotive coatings, outdoor plastics.
Gross margin: 19.04% (1H2026); 17.70% (FY2025); 18.24% (FY2024).
Momentum: Fastest-growing major line (+31.1% in 1H2026).
Phthalocyanine pigments (3.9% of 1H2026 revenue)
Description: Copper-phthalocyanine blues and greens.
Applications: Inks, coatings, plastics.
Trend: Revenue −7.7% in 1H2026 to CNY 31.09M. Margin not disclosed.
Other organic pigments (5.3% of 1H2026 revenue)
Description: Organic pigments outside the three main chemistries (not itemised).
Trend: +36.2% in 1H2026 to CNY 42.13M.
Acid dyes and other main business (7.1% of 1H2026 revenue)
Description: Acid dyes for nylon, wool, silk and blended fabrics; inkjet ink colourants; waterborne wood-lacquer colourants (2026 Interim Report).
Trend: "Other main business" +64.4% in 1H2026 to CNY 56.43M.
Services and capabilities bundled with products
| Capability | Specification | Source |
|---|---|---|
| Portfolio breadth | 450+ pigment specifications | 2026 Interim Report |
| Testing | 200+ test methods; grinding/dispersion equipment simulating customer production | 2026 Interim Report |
| Application labs | Coatings, plastics and ink application laboratories | 2026 Interim Report |
| Regulatory | 89 EU REACH registrations completed in-house; MSDS in ~30 languages (EN, FR, DE, ES, PT, KO, JA and others); EHS team for 15+ years | 2026 Interim Report |
| Logistics | Shanghai logistics centre (5,500 m² lease); warehouses in US, Canada, Netherlands, Turkey, UK, Australia | 2026 Interim Report |
| Customisation | Application-specific development with customer co-testing | 2026 Interim Report |
| Core technologies | Organic-pigment surface treatment; organic-pigment testing; control of negative (restricted) substances | 2026 Interim Report |
Pipeline products
The proposed CB-funded "dye/pigment high-performance post-treatment" project (CNY 230M, Jinzhou) would apply finishing processes to both self-produced and outsourced pigments to improve weatherfastness and tinting strength — effectively a margin-enhancement service layer on the existing product range rather than new chemistry. Liaoning Xinkai is reported to be "gradually launching new products with good validation feedback from downstream customers" (CB feasibility report, Jul 2026); specific products are not named.
Financial Narrative
Sources: FY2021 — IPO prospectus summary (Jiemian / prospectus data table); FY2022–FY2024 — audited data in IPO listing announcement (15 Apr 2025); FY2025 — CB dilution announcement (Jul 2026), Eastmoney, and opening balances of the 2026 Interim Report; 1H data — 2026 Interim Report. All CNY M.
Income statement
FY2025 revenue is derived from the reported 7.33% decline on FY2024 (Eastmoney reports CNY 1.313bn). FY2025 operating profit, EBITDA and pre-tax income were not available in the sources reviewed.
FY2025 basic EPS on the weighted share count is not confirmed; using the aggregator's FY2025 deducted EPS of CNY 0.97 implies a weighted share base of ~85.6M and basic EPS of ~CNY 0.91 (derived). Diluted EPS equals basic (no dilutive instruments outstanding). FY2024 and FY2025 dividends: CNY 1.50 per 10 shares (CNY 14.06M each), per the 2024 profit distribution announcement and the 1H2026 equity statement.
FY2024 gross margin of 14.34% is from moomoo key indicators (secondary, reported as of Apr 2025). Company-level gross margin for 1H2026 is 18.27% (derived: revenue 791.58 less cost 646.92) versus 16.25% for 1H2025.
Revenue CAGR FY2021–FY2025 (derived): ~2.1% per annum. Revenue is essentially flat across the period, with a cyclical trough in FY2023 (destocking across global ink and coatings chains) and a peak in FY2024.
Interim comparison (2026 Interim Report)
Commentary: The 1H2026 print shows strong operational momentum masked by currency. Gross profit rose 27% and opex fell, but a CNY 36M swing in finance costs — from a CNY 17.2M gain to an CNY 18.9M charge, which the company attributes mainly to RMB appreciation against USD and EUR — wiped out the operating gain. Inventory write-downs doubled to CNY 8.0M. EPS fell 16% because of the full-period effect of the IPO share issuance.
Balance sheet
1H2026 balance sheet (30 Jun 2026): Total assets CNY 2,026.09M; cash CNY 394.03M (of which CNY 99.94M restricted — acceptance-bill margins, FX forward margins, pledged deposits and a litigation freeze); receivables CNY 294.41M; inventory CNY 382.58M; long-term equity investments CNY 91.26M; fixed assets CNY 506.01M; construction in progress CNY 97.27M; short-term borrowings CNY 180.99M; long-term borrowings CNY 133.28M; current portion of non-current liabilities CNY 32.45M; notes payable CNY 344.35M; accounts payable CNY 206.03M; total liabilities CNY 963.64M; attributable equity CNY 1,008.15M; minority interests CNY 54.29M. Goodwill: nil. The company states bank loans totalled ~CNY 336M at 30 Jun 2026 (CB feasibility report).
Note: CNY 344M of bank acceptance notes payable is a significant quasi-financing item excluded from the above; including it would put the group in a net-debt position of roughly CNY 386M at 1H2026 (derived).
Cash flow
Capex was not separately captured for FY2022–FY2025, but investing outflows of CNY 124–160M per year during FY2022–FY2024 are consistent with the Liaoning build-out. No share buybacks have been authorised or executed. 1Q2026 operating cash flow was −CNY 31.92M (Eastmoney).
Ratios
Notes: FY2025 ROA uses attributable net income (total net income not captured). 1Q2026 current ratio 1.57x, quick ratio 1.03x, liabilities-to-assets 45.34% (CB plan). Cash conversion cycle at 1H2026: 12.67 days (Lixinger, secondary), with receivable days ~58. ROIC and net debt/EBITDA are not publicly disclosed and cannot be robustly derived because FY2025 EBITDA was not available; on FY2024 data the group was near net-neutral on bank debt.
Trend commentary
Growth: The top line has been range-bound at CNY 1.07–1.42bn for five years. FY2024's 32.5% surge reflected post-destocking restocking by multinational customers and new Liaoning output; FY2025's 7.3% decline reflected weaker export pricing and US tariff friction. 1H2026's 13.2% rebound — led by domestic sales (+70%) and heterocyclic pigments (+31%) — suggests FY2026 revenue could recover toward FY2024 levels, though management provides no guidance.
Profitability: Attributable net margins have been remarkably stable at 7.3–8.2% (FY2021–FY2024) before falling to 5.9% in FY2025. The FY2025 compression is explained by lower revenue, losses at the Liaoning manufacturing subsidiaries, and FX. Notably, FY2025 deducted net profit (CNY 83.0M) exceeded reported net profit (CNY 77.8M), meaning non-recurring items (principally FX derivative fair-value losses) were a net drag.
Balance sheet: The IPO (net proceeds CNY 243.85M) de-levered the group from 58% to 46% liabilities-to-assets. However, the company is now re-levering (short-term borrowings up 70% in 1H2026) to fund working capital and capex, and plans a CNY 450M CB — a sign that the IPO raise was undersized relative to the manufacturing ambition (the company itself describes the prior raise as "relatively small and basically used up").
Cash flow: Operating cash flow covered net income in FY2022–FY2024 (cash conversion ~0.9–1.4x), but capex has consistently exceeded OCF, producing negative free cash flow during the build-out.
FX sensitivity: Exchange gains/losses swing materially: FY2021 loss CNY 10.94M; FY2022 gain CNY 13.73M; FY2023 gain CNY 8.32M; 1H2024 gain CNY 3.78M; 1H2026 net finance charge of CNY 18.90M mainly from FX. On a 1H2026 pre-tax profit of CNY 65M, a CNY 36M year-on-year FX swing is highly material.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Azo pigments revenue | 721 | 903 | 847 |
Heterocyclic pigments revenue | — | 285 | 259 |
All other lines incl. phthalocyanine, other pigments, acid dyes, other business (derived residual) | — | 229 | 207 |
Total operating revenue | 1,069 | 1,417 | 1,313 |
Product line gross margin (%)
| Product line gross margin (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Azo pigments gross margin | 15.61 | 13.92 | 15.14 |
Heterocyclic pigments gross margin | 17.62 | 18.24 | 17.70 |
Product line share of revenue (%)
| Product line share of revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Azo pigments share | 67.42 | 63.77 | 64.52 |
Heterocyclic pigments share | — | 20.08 | 19.76 |
Product line YoY growth (%)
| Product line YoY growth (%) | FY2024 | FY2025 |
|---|---|---|
Azo pigments YoY | 25.2 | -6.2 |
Heterocyclic pigments YoY | — | -9.1 |
Total revenue YoY | 32.5 | -7.3 |
Product Lines (1H2025–1H2026)
| Product line (CNY Mn) | 1H2025 | 1H2026 |
|---|---|---|
Azo pigments | 458.50 | 477.35 |
Heterocyclic pigments | 134.95 | 176.94 |
Phthalocyanine pigments | 33.69 | 31.09 |
Other organic pigments | 30.94 | 42.13 |
Other main business (incl. acid dyes) | 34.34 | 56.43 |
Other business | 6.66 | 7.63 |
Total | 699.08 | 791.58 |
Product line (1H2026) | Revenue share % | YoY % |
Azo pigments | 60.30 | +4.11 |
Heterocyclic pigments | 22.35 | +31.11 |
Phthalocyanine pigments | 3.93 | −7.72 |
Other organic pigments | 5.32 | +36.17 |
Other main business | 7.13 | +64.35 |
Chemical industry total | 99.04 | +13.22 |
Group Entities
| Entity | Location | Ownership | Function |
|---|---|---|---|
Zhejiang Haochuan Technology Co., Ltd. (浩川科技) | Zhejiang | Controlled | R&D; provincial-level HNTE R&D centre; 15% tax rate |
Shanghai Canglong Supply Chain Management Co., Ltd. (上海仓隆) | Shanghai | Controlled | Supply chain/logistics; small-profit enterprise |
Liaoning Xinkai Industrial Co., Ltd. (辽宁信凯) | Jinzhou, Liaoning | 74.60% | Manufacturing — azo dyes/pigments (10,000 t project); environmental-disclosure-listed entity |
Liaoning Xinkai Ziyuan New Materials Co., Ltd. (辽宁紫源) | Jinzhou Binhai New Area, Liaoning | 79% (21% Wuxi Wucai Industrial Investment LP) | Pigment manufacturing; registered capital CNY 150M |
Hangzhou Yuancai Enterprise Management LP (杭州源彩) | Hangzhou | Controlled partnership | Holding/incentive vehicle |
Trust Chem Hong Kong Ltd. | Hong Kong | Controlled | Trading/holding (USD functional) |
TCC Development Hong Kong Ltd. | Hong Kong | Controlled | Holding (USD functional) |
Worldwide Colorants & Chemical Co., Ltd. | Hong Kong | Controlled | Trading brand entity (USD functional) |
Trust Chem Europe B.V. | Netherlands | Controlled | Sales, warehousing (EUR) |
Trust Chem USA, LLC | United States | Controlled | Sales, warehousing (USD) |
Trust Chem Canada Ltd. | Canada | Controlled | Sales, warehousing |
Worldwide Colorants and Chemicals Australia Pty Ltd. | Australia | Controlled | Sales, warehousing |
Trust Chem Pigments Private Ltd. | India | Controlled | Sales (INR) |
Trust Chem Turkey Pigment Ltd. Şti. | Turkey | Controlled | Sales, warehousing (TRY) |
Trust Chem UK Pigments Ltd. | United Kingdom | Controlled | Sales, warehousing (GBP) |
Wenzhou Jinyuan New Material Technology Co., Ltd. (温州金源) | Wenzhou, Zhejiang | Associate (equity method) | Pigment production; key related-party supplier; financials exempted from disclosure |
Group Entities by Subsidiary
| Subsidiary | Total assets | Net assets | Revenue | Operating profit | Net profit |
|---|---|---|---|---|---|
Trust Chem Europe B.V. | 173.01 | 14.21 | 169.22 | 16.41 | 12.28 |
Trust Chem USA, LLC | 125.78 | 31.55 | 146.69 | 8.73 | 6.52 |
Results by Segment and Segment Assets & Liabilities
| Liaoning Xinkai Industrial (CNY Mn) | FY2024 (audited) | 1Q2025 (unaudited) |
|---|---|---|
Revenue | 100.56 | 36.31 |
Total profit | -33.75 | -8.09 |
Net profit | -24.97 | -6.08 |
Total liabilities | 282.74 | 319.25 |
Net assets | 148.73 | 142.65 |
Income statement (CNY Mn)
| Income statement (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 1,205.67 | 1,192.39 | 1,068.72 | 1,416.57 | 1,312.75 |
Operating profit | — | 110.03 | 104.27 | 131.56 | — |
EBITDA (company-defined) | — | 124.97 | 122.44 | 167.42 | — |
Pre-tax income | — | 113.39 | 104.39 | 131.52 | — |
Net income (total) | — | 85.31 | 84.55 | 104.85 | — |
Net income attributable to parent | 89.02 | 87.65 | 88.06 | 110.97 | 77.82 |
Attributable net income excl. non-recurring items | — | 91.09 | 83.44 | 104.91 | 83.02 |
Per-share data (CNY)
| Per-share data (CNY) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Basic EPS (derived; pre-IPO share count 70.30M) | 1.25 | 1.25 | 1.58 | — |
Basic EPS excl. non-recurring (reported/aggregator) | — | 1.18 | 1.49 | 0.97 |
Dividend per share | — | — | 0.15 | 0.15 |
Margins (%)
| Margins (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (company-level) | — | — | — | 14.34 | — |
Operating margin (derived) | — | 9.23 | 9.76 | 9.29 | — |
EBITDA margin (derived) | — | 10.48 | 11.46 | 11.82 | — |
Net margin attributable (derived) | 7.38 | 7.35 | 8.24 | 7.83 | 5.93 |
Income Statement and Per-Share Data
| Line item (CNY Mn) | 1H2025 | 1H2026 | YoY % |
|---|---|---|---|
Revenue | 699.08 | 791.58 | +13.23 |
Cost of sales | 585.49 | 646.92 | +10.49 |
Gross profit (derived) | 113.59 | 144.66 | +27.4 |
Selling expenses | 30.96 | 29.87 | −3.53 |
Administrative expenses | 25.20 | 21.87 | −13.21 |
R&D expenses | 3.60 | 7.71 | +114.06 |
Finance costs (net) | −17.24 | 18.90 | — |
— of which interest expense | 3.26 | 4.78 | +46.5 |
Investment income (mainly associate) | 11.54 | 10.16 | −12.0 |
Fair-value gains | −10.89 | 2.06 | — |
Credit impairment | −2.07 | −4.90 | — |
Asset (inventory) impairment | −3.63 | −8.04 | — |
Operating profit | 65.27 | 64.71 | −0.86 |
Total profit | 65.34 | 65.10 | −0.36 |
Income tax | 14.34 | 12.99 | −9.45 |
Net profit attributable | 54.57 | 55.07 | +0.92 |
Net profit attributable excl. non-recurring | 61.32 | 52.55 | −14.29 |
Basic EPS (CNY) | 0.70 | 0.59 | −15.71 |
Weighted ROE (%) | 7.05 | 5.52 | −1.53pp |
Balance Sheet
| Balance sheet (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 983.45 | 1,083.14 | 1,332.34 | 1,753.90 | 1,893.91 |
Current assets | — | 670.41 | 753.30 | 998.02 | 1,056.64 |
Current liabilities | — | 507.61 | 569.29 | 835.15 | 711.34 |
Working capital (derived) | — | 162.81 | 184.01 | 162.87 | 345.30 |
Cash and equivalents (monetary funds) | — | — | — | 371.99 | 309.22 |
Inventory | — | — | — | 338.55 | 379.90 |
Accounts receivable | — | — | — | 221.52 | 213.48 |
Short-term borrowings | — | — | — | — | 106.74 |
Long-term borrowings | — | — | — | — | 108.67 |
Notes payable (bank acceptances) | — | — | — | — | 379.93 |
Total liabilities | — | 572.81 | 714.21 | 1,020.14 | 862.56 |
Total equity | — | 510.34 | 618.13 | 733.76 | 1,031.35 |
Equity attributable to parent | 351.89 | 454.38 | 549.59 | 664.75 | 972.30 |
Goodwill | — | — | — | — | 0 |
Intangible assets (mainly land use rights) | — | — | — | — | 84.43 |
Net debt (CNY Mn, derived)
| Net debt (CNY Mn, derived) | FY2025 | 1H2026 |
|---|---|---|
Bank borrowings (ST + LT + current portion, approx.) | 232 | 336 |
Cash (gross) | 309 | 394 |
Net debt (negative = net cash), gross cash basis | -77 | -58 |
Net debt excluding restricted cash | — | 42 |
Cash flow (CNY Mn)
| Cash flow (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating cash flow | 102.99 | 121.26 | 94.73 | — |
Investing cash flow | -159.80 | -124.32 | -153.66 | — |
Financing cash flow | 22.04 | 33.89 | 93.59 | — |
FX effect on cash | 17.49 | 8.83 | 12.73 | — |
Net change in cash | -17.28 | 39.66 | 47.40 | — |
Dividends paid to parent shareholders | — | — | — | 14.06 |
Cash flow (CNY Mn) (1H2025–1H2026)
| Cash flow (CNY Mn) | 1H2025 | 1H2026 |
|---|---|---|
Operating cash flow | -37.93 | 39.67 |
Capex (purchase of PP&E/intangibles) | 30.91 | 68.66 |
Free cash flow (derived, OCF − capex) | -68.84 | -28.99 |
Investing cash flow | -50.31 | -15.58 |
Financing cash flow | 195.90 | 93.43 |
Dividends and interest paid | 4.97 | 20.07 |
FX effect on cash | 6.84 | -14.66 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on avg attributable equity (%, derived) | 21.7 | 17.5 | 18.3 | 9.5 |
ROA on avg total assets (%, derived) | 8.3 | 7.0 | 6.8 | 4.3 |
Current ratio (x) | 1.32 | 1.32 | 1.20 | 1.49 |
Quick ratio (x) | 0.91 | 0.94 | 0.79 | 0.95 |
Liabilities-to-assets (%) | 52.88 | 53.61 | 58.16 | 45.54 |
Total liabilities / total equity (x, derived) | 1.12 | 1.16 | 1.39 | 0.84 |
Interest coverage (x) | 22.05 | 20.23 | 17.11 | — |
Asset turnover (x) | 1.15 | 0.88 | 0.92 | — |
Receivables turnover (x) | 5.85 | 5.50 | 6.65 | — |
Inventory turnover (x) | 4.65 | 4.19 | 4.36 | — |
Overseas share of main-business revenue (%)
| Overseas share of main-business revenue (%) | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Overseas share | 84.90 | 86.45 | 88.20 |
United States share | 9.33 | 13.02 | 13.67 |
Revenue by Region
| Region (CNY Mn) | 1H2025 | 1H2026 |
|---|---|---|
Domestic main-business revenue | 86.45 | 147.12 |
Overseas main-business revenue | 605.97 | 636.83 |
Other business | 6.66 | 7.63 |
Region (1H2026) | Share of revenue % | YoY % |
Domestic | 18.59 | +70.18 |
Overseas | 80.45 | +5.09 |
Share Price & Returns
| Reference point | Price (CNY) | Implied return to CNY 33.32 (1 Sep 2026) |
|---|---|---|
IPO issue price (Apr 2025) | 12.80 | +160% |
First-day open (15 Apr 2025) | 51.00 | −35% |
52-week high (to Aug 2026) | 58.68 | −43% |
52-week low (to Aug 2026) | 26.95 | +24% |
Approx. start of 2026 (derived from −30.91% YTD at CNY 33.97 on 8 Jul 2026) | ~49.2 | −32% |
Period return | Value | — |
1-year (to 9 Aug 2026) | −18.99% (Investing.com) | — |
3-year | n/a (listed Apr 2025) | — |
5-year | n/a (listed Apr 2025) | — |
Annualised since listing (to 1 Sep 2026) | −18.71% (Lixinger, measured from first trading price) | — |
Valuation Multiples
| Multiple | Trust Chem | Lily Group | Qicai Chemical | Basis |
|---|---|---|---|---|
P/E (TTM) | 39.9 | ~147 (dynamic) | ~58 (dynamic) | Lixinger; 10jqka (Jul 2026) |
P/B | 3.10 | 10.10 | 2.04 | Same |
EV/Sales (TTM, derived) | ~2.2 | not computed | not computed | EV ≈ CNY 3.12bn; TTM revenue CNY 1.405bn |
Dividend yield | 0.45% | — | — | Lixinger |
Dividend (CNY)
| Dividend (CNY) | FY2024 | FY2025 |
|---|---|---|
DPS | 0.15 | 0.15 |
Total cash dividend (CNY Mn) | 14.06 | 14.06 |
Payout ratio (%, derived) | 12.7 | 18.1 |
Capital Markets
| Item (30 Jun 2026) | CNY Mn |
|---|---|
Short-term borrowings | 180.99 |
Current portion of non-current liabilities | 32.45 |
Long-term borrowings | 133.28 |
Lease liabilities (non-current) | 2.55 |
Notes payable (bank acceptances, ≤1 year) | 344.35 |
Shares by Date
| Date | Shares | % of total | Holders |
|---|---|---|---|
15 Oct 2025 (expired) | 471,269 | 0.50 | Offline placement investors |
15 Apr 2026 (expired) | 2,109,140 | 2.25 | Ningbo Huikai Century VC |
15 Apr 2028 | 68,195,530 | 72.75 | Senyuan, Li Zhi, Li Wu, Lishijia |
Analyst Conclusions
Management guidance
No formal guidance. Management's qualitative signals (2026 Interim Report; CB filings): continued globalisation and manufacturing upgrade, partial pass-through of freight costs, R&D centre in service by mid-2027, Liaoning base as the group's high-value technology-transformation platform, and deleveraging via CB proceeds.
Consensus growth expectations
Not publicly disclosed (no sell-side consensus identified). The company's own illustrative scenarios in the CB dilution filing (flat, +10% and +20% annual net profit growth from CNY 77.82M) are explicitly not forecasts. For reference, simple annualisation of 1H2026 implies revenue of ~CNY 1.5–1.6bn for FY2026 if seasonality mirrors prior years (analyst arithmetic, not a forecast).
Bull case
-
Operating inflection is already visible: 1H2026 gross profit rose 27% on 13% revenue growth, with overseas gross margin up ~3pp to 20.4% and opex down; once FX normalises, the operating leverage flows through to earnings.
-
Mix migration to HPP: Heterocyclic pigments grew 31% and the CB-funded post-treatment project targets exactly the higher-margin performance segment where Western capacity (Heubach) has exited.
-
Moat plus valuation support: An 11-year export-leadership record, 89 REACH registrations and decade-long blue-chip relationships underpin a franchise trading at ~2.2x EV/Sales and ~3x P/B — far below theme-driven peers such as Lily (~10x P/B).
Bear case
-
Capital allocation is eroding returns: ROE fell from ~18% (FY2024) to ~9.5% (FY2025, derived) as the asset base doubled; manufacturing subsidiaries remain loss-making and projects are repeatedly delayed.
-
FX, tariffs and freight are structural, not cyclical: With 80%+ of revenue overseas, a CNY 36M FX swing on CNY 65M of pre-tax profit (1H2026) shows earnings are hostage to macro variables the company cannot control.
-
Valuation is not cheap on earnings: ~40x TTM P/E for a business with ~6% net margins, flat five-year revenue (2.1% CAGR), under 1% R&D intensity and an incoming CB of up to ~14% of market cap; 20% of float is margin-financed, amplifying downside.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | 3Q2026 results — test of whether revenue growth and margin gains persist and FX losses moderate |
| 4Q2026–1H2027 | SZSE review and CSRC registration of the ≤ CNY 450M CB; coupon, conversion price and rating |
| 2H2026–1H2027 | Completion of the 1,500 t organic pigment project (92% done) and Liaoning loss trajectory (minority-share losses as proxy) |
| By 30 Jun 2027 | R&D Centre & HQ completion (any third delay would damage credibility) |
| Ongoing | USD/CNY and EUR/CNY; US tariff actions on Chinese chemicals; China–Europe/US container rates |
| Apr 2027 | FY2026 annual report and dividend decision |
| Ongoing | Related-party purchases from Wenzhou Jinyuan versus the CNY 92M cap |
| Ongoing | Margin-financing balance and shareholder count as sentiment indicators |
Analyst verdict
Trust Chem is a genuinely differentiated asset within China's crowded pigment sector: it is not the largest producer, but it is the most internationally embedded, with a decade-plus record as the country's leading exporter, a regulatory compliance apparatus that few domestic peers can match, and customer relationships with the world's top ink and coatings formulators. That franchise generated attractive, capital-light returns — derived ROE of roughly 17–22% through FY2024 — on a business that has nonetheless never grown much: revenue in FY2025 was only about 9% above FY2021.
The company is now making a deliberate, and costly, bet that vertical integration will solve its core structural weakness — thin margins inherent to a trading model. The evidence so far is mixed. On the positive side, 1H2026 delivered the strongest gross-profit growth since listing, a visible shift toward high-performance heterocyclic pigments and margin expansion overseas. On the negative side, the Liaoning manufacturing subsidiaries remain loss-making, the IPO-funded R&D headquarters has been delayed twice, return on equity has roughly halved, and the company is returning to the market for up to CNY 450M only fifteen months after its IPO, after describing its first raise as too small.
Reported earnings remain highly sensitive to the renminbi, freight and US tariffs — none of which management can control — and at roughly 40 times trailing earnings, the shares already discount a successful transition. The stock has de-rated sharply from its first-day euphoria, and its tightly held, retail- and margin-dominated register adds volatility.
Verdict: Neutral / "show-me" stance. The franchise is real and the operating trend is improving, but the investment case requires proof that manufacturing integration lifts consolidated gross margin sustainably above ~20% and restores ROE toward mid-teens without excessive dilution. The 3Q2026 results, CB terms and Liaoning profitability are the decisive monitorables over the next twelve months.
Data limitations: The FY2025 annual report full text (segment detail, FY2025 cash flow, R&D and EBITDA) and FY2021–FY2025 annual R&D figures were not available in the sources reviewed; such items are marked accordingly. Market data are as of the latest verified quote (1 Sep 2026) and should be refreshed. Derived figures are analyst computations from disclosed data.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / start | Background | Age / born | Education |
|---|---|---|---|---|---|
Li Zhi (李治) | Chairman & General Manager; legal representative | Founder (1996); Chairman since Sep 2021 | Sales manager, China National Chemicals Import & Export Corp. Zhejiang branch (1991–94); senior manager, Hong Kong Longyuan Trading (1994–96); executive director/GM of predecessor (1996–2021); also chairs Liaoning Xinkai and Liaoning Ziyuan; director of Xinkai Senyuan, Haochuan, BOSON | Born Oct 1969 (56–57) | MBA, Zhejiang University of Technology; HK permanent residency |
Li Wu (李武) | Director & Technical Director | Co-founder (1996) | Teacher, School of Biological & Chemical Engineering, Zhejiang University of Science & Technology (since 1986); technical director of predecessor (1996–2021); vice-chair of Liaoning Xinkai and Liaoning Ziyuan; director of Wenzhou Jinyuan and BOSON; former chairman of Anshan Huihong New Materials | Born Jul 1967 (59) | Diploma in chemical engineering, Zhejiang University of Science & Technology; study at Emden-Leer University (Germany) 1993–94 |
Liu Jianbing (刘建兵) | Director & CFO (head of accounting) | — | — | — | — |
Jiang Wei (蒋炜) | Director & HR/Administration Director | — | — | Born Sep 1980 | — |
Shen Rijiong (沈日炯) | Independent Director | — | — | — | — |
Shi Fang (施放) | Independent Director | — | — | — | — |
Liang Weiliang (梁伟亮) | Independent Director (accounting expert) | — | CFO, Hangzhou Hexing Electric (2015–17); director & CFO, Borui Energy Environmental Engineering (2017–20); VP, Fancheng Design (2020–22); director, Zhejiang Samsung Thermal Power | Born Nov 1973 | BA Accounting, Zhejiang University of Finance & Economics; senior accountant; non-practising CICPA member |
Huang Tao (黄涛) | Board Secretary & Procurement Manager | — | — | — | — |
Sun Xucong (孙旭聪) | Head of Accounting Department | — | — | — | — |
Yang Qinhua (杨沁桦) | Securities Affairs Representative | — | — | — | — |
“—” = not publicly disclosed.
Board of Directors (Annual)
| Name | Role | FY2024 total pay | FY2025 total pay |
|---|---|---|---|
Li Zhi | Chairman & GM | 851.3 | 1,048.1 |
Li Wu | Director & Technical Director | 577.5 | 698.8 |
Liu Jianbing | Director & CFO | 596.8 | — |
Jiang Wei | Director & HR/Admin Director | 562.0 | — |
Shen Rijiong | Independent Director | 78.0 | — |
Shi Fang | Independent Director | 78.0 | — |
Liang Weiliang | Independent Director | 78.0 | — |
Huang Tao | Board Secretary | 375.4 | — |
Major Shareholders
| Rank | Shareholder | Type | Shares | Stake % | Restricted until |
|---|---|---|---|---|---|
| 1 | Zhejiang Xinkai Senyuan Investment (Li Zhi 65%, Li Wu 35%) | Domestic non-state legal person | 40,000,000 | 42.67 | 15 Apr 2028 |
| 2 | Li Zhi | Individual | 16,250,000 | 17.34 | 15 Apr 2028 |
| 3 | Li Wu | Individual | 8,750,000 | 9.33 | 15 Apr 2028 |
| 4 | Hangzhou Lishijia Enterprise Management LP (GP: Li Zhi) | Partnership | 3,195,530 | 3.41 | 15 Apr 2028 |
| 5 | Ningbo Huikai Century Venture Capital LP (formerly Huzhou Huikai) | Partnership | 2,106,140 | 2.25 | Unrestricted since 15 Apr 2026 (sold 3,000 shares in 1H2026) |
| 6 | Feng Wei | Individual (margin account) | 832,600 | 0.89 | — |
| 7 | Wu Aijun | Individual | 456,165 | 0.49 | — |
| 8 | Tong Zheng | Individual | 380,100 | 0.41 | — |
| 9 | Wu Nan | Individual | 349,600 | 0.37 | — |
| 10 | Suzhou Hongweisite Electronic Technology | Legal person | 307,200 | 0.33 | — |
Competitive Landscape
Key Competitors
| Competitor | Country | Overlap with Trust Chem | Positioning vs. Trust Chem |
|---|---|---|---|
Lily Group (百合花, 603823.SH) | China | Azo, phthalocyanine, HPP; inks/coatings/plastics | Integrated manufacturer; claims ~10% global organic-pigment share; larger scale |
Anshan Qicai Chemical (七彩化学, 300758.SZ) | China | HPP (benzimidazolone), solvent dyes | Higher-margin HPP manufacturer; also in Liaoning |
Shuangle Pigment (双乐股份, 301036.SZ) | China | Phthalocyanine, classic pigments | Manufacturer; first-tier domestic |
Longkou Union Chemical (联合化学, 301209.SZ) | China | Azo/classic pigments | Manufacturer; first-tier domestic |
Changshan Beiming / Sunshine Pigment / Jiehong Pigment | China | Classic pigments | Second-tier domestic producers |
Sun Chemical (DIC Group) | Japan/US | Full range (incl. former BASF pigments acquired 2021) | Global leader — and a Trust Chem customer (co-opetition) |
Heubach Group (incl. former Clariant pigments) | Germany | Full range incl. HPP | — |
Sudarshan Chemical Industries | India | Organic pigments | Consolidator post-Heubach; global reach |
Indian classic-pigment exporters (e.g., Meghmani-type producers) | India | Azo/phthalocyanine exports | Price competitors in export markets |
Toyocolor (artience Group) | Japan | Pigments for inks/plastics | Asian incumbent |
Peer Comparison FY2025
| Metric | Trust Chem (001335) | Lily Group (603823) | Qicai Chemical (300758) |
|---|---|---|---|
1Q2026 revenue (CNY Mn) | 382.1 | 573 | 401 |
Revenue YoY (%) | +8.92 | +0.74 | +9.77 |
1Q2026 net profit (CNY Mn) | 24.2 | 43 | 16 |
Net profit YoY (%) | +3.05 | −6.22 | −48.64 |
Net margin (%, derived) | 6.3 | 7.5 | 4.0 |
Gross margin (%) | not disclosed for 1Q (1H2026: 18.27) | 20.02 | 29.19 |
Market cap (CNY Bn, Jul 2026) | ~2.8–3.1 | ~25.2 | ~3.6 |
P/E (TTM / dynamic) | ~36–40 | ~147 (dynamic) | ~58 (dynamic) |
R&D intensity | ~1% (1H2026) | — | — |



